The article discusses the effectiveness of early thrombolytic treatment in acute myocardial infarction (AMI), emphasizing the importance of treatment timing. It presents data from 22 randomized trials involving 50,246 patients, showing that fibrinolytic therapy saves more lives when administered within the first 3 hours of symptom onset. The benefit was highest in patients treated within 1 hour, with 65 additional lives saved per 1000 treated patients. The relationship between treatment delay and mortality reduction was better described by a non-linear regression model than a linear one. The study also highlights that patients treated within 2 hours had a significantly higher mortality reduction (44%) compared to those treated later (20%). The analysis challenges the FTT findings, suggesting that very early treatment can provide substantial benefits. The article supports the concept of a "first golden hour" for AMI treatment, where prompt intervention significantly improves outcomes. It concludes that initiating fibrinolytic therapy within 2-3 hours after symptom onset is crucial for optimal results, and emphasizes the need for public awareness and rapid diagnosis to minimize treatment delays.The article discusses the effectiveness of early thrombolytic treatment in acute myocardial infarction (AMI), emphasizing the importance of treatment timing. It presents data from 22 randomized trials involving 50,246 patients, showing that fibrinolytic therapy saves more lives when administered within the first 3 hours of symptom onset. The benefit was highest in patients treated within 1 hour, with 65 additional lives saved per 1000 treated patients. The relationship between treatment delay and mortality reduction was better described by a non-linear regression model than a linear one. The study also highlights that patients treated within 2 hours had a significantly higher mortality reduction (44%) compared to those treated later (20%). The analysis challenges the FTT findings, suggesting that very early treatment can provide substantial benefits. The article supports the concept of a "first golden hour" for AMI treatment, where prompt intervention significantly improves outcomes. It concludes that initiating fibrinolytic therapy within 2-3 hours after symptom onset is crucial for optimal results, and emphasizes the need for public awareness and rapid diagnosis to minimize treatment delays.